Section 4: Clinical Pharmacy Services

4CPS-092

EVALUATION OF AGGRESSIVENESS OF CANCER CARE NEAR THE END OF LIFE IN PATIENTS WITH METASTATIC NON-MICROCYTIC LUNG CANCER (submitted in 2019)

4CPS-091

EVALUATION OF AGGRESSIVENESS OF CANCER CARE NEAR THE END OF LIFE IN PATIENTS WITH PANCREATIC CANCER (submitted in 2019)

4CPS-090

EFFICACY AND SAFETY OF ERLOTINIB IN NON-SMALL CELL LUNG CANCER (submitted in 2019)

4CPS-089

COMPARATIVE EFFECTIVENESS OF NINTEDANIB PLUS DOCETAXEL VERSUS DOCETAXEL MONOTHERAPY IN ADENOCARCINOMA NON-SMALL CELL LUNG CANCER (submitted in 2019)

4CPS-088

CHECKPOINT INHIBITORS IN NON-MICROCYTIC LUNG CANCER: RESULTS IN COMMON CLINICAL PRACTICE (submitted in 2019)

4CPS-087

OPTIMISATION OF RESOURCES IN THE USE OF IMUNOTHERAPY: NIVOLUMAB AND PEMBROLIZUMAB IN WEIGHT-BASED DOSING INSTEAD OF FLAT DOSE. (submitted in 2019)

4CPS-086

IMATINIB DOSE OPTIMISATION THROUGH THERAPEUTIC MONITORING IN CHRONIC MYELOID LEUKAEMIA AS PART OF PHARMACEUTICAL CARE (submitted in 2019)

4CPS-085

IMPROVED ACCESS TO CHEMOTHERAPEUTIC TREATMENT IN PATIENTS WITH MULTIPLE MYELOMA (submitted in 2019)

4CPS-084

ANTHRACYCLINES DOSAGE IN PAEDIATRIC OBESE PATIENTS (submitted in 2019)

4CPS-083

SAFETY AND TOLERABILITY OF PALBOCICLIB IN CLINICAL PRACTICE IN A TERTIARY HOSPITAL (submitted in 2019)

4CPS-082

RISK OF MYELOTOXICITY IN NON-CANCER PATIENTS TREATED WITH CHEMOTHERAPY (submitted in 2019)

4CPS-081

GEFITINIB IN NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY. (submitted in 2019)

4CPS-080

REAL LIFE TYROSINE KINASE INHIBITOR DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (submitted in 2019)

4CPS-079

SEQUENCING OF IBRUTINIB, IDELALISIB AND VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKAEMIA: EXPERIENCE IN A TERTIARY HOSPITAL (submitted in 2019)

4CPS-078

EFFECTIVENESS AND SAFETY OF ERIBULIN FOR ADVANCED BREAST CANCER TREATMENT (submitted in 2019)

Pages